脑心通胶囊联合贝那普利治疗原发性高血压的临床研究

目的探讨脑心通胶囊联合贝那普利治疗原发性高血压的安全性和有效性。方法选取内江市中医医院2014年12月—2015年12月收治的原发性高血压患者161例,随机分成对照组(80例)和治疗组(81例)。对照组患者口服盐酸贝那普利片,10 mg/d,1次/d。治疗组患者在对照组的基础上口服脑心通胶囊,2粒/次,3次/d。两组患者均连续服用1个月。比较治疗前后两组患者临床疗效、血压和血脂变化以及1年内并发症发生情况。结果治疗后,对照组和治疗组的临床有效率分别为82.50%、97.53%,两组比较差异具有统计学意义(P0.05)。治疗后,两组患者收缩压和舒张压均明显降低(P0.05);且治疗组患者收缩压和舒张压下降幅度明显优于对照组(P0.05)。治疗后,两组患者低密度脂蛋白、三酰甘油和胆固醇水平均明显降低(P0.05);且治疗组患者上述血脂降低水平优于对照组(P0.05)。治疗后1年内,对照组患者并发症总发生率为32.50%,显著高于治疗组的13.58%,两组并发症发生率比较差异具有统计学意义(P0.05)。治疗期间对照组和治疗组的不良反应发生率分别为21.25%、7.41%,两组比较差异具有统计学意义(P0.05)。结论脑心通胶囊联合贝那普利治疗原发性高血压能够显著降低血压水平,同时可改善患者血脂和并发症发生,具有一定的临床推广应用价值。

Clinical study on Naoxintong Capsules combined with benazepril in treatment of primary hypertension

Objective To explore the safety and efficacy of Naoxintong Capsules combined with benazepril in treatment of primary hypertension. Methods Patients (161 cases) with primary hypertension in Neijiang Traditional Chinese Medicine Hospital from December 2014 to December 2015 were randomly divided into control (80 cases) and treatment (81 cases) groups. Patients in the control group were po administered with Benazepril Hydrochloride Tablets, 10 mg/d, once daily. Patients in the treatment group were po administered with Naoxintong Capsules on the basis of the control group, 2 grains/time, three times daily. Patients in two groups were treated for 1 month. After treatment, the clinical efficacy, change of blood pressure and blood lipid, and complication occurred within 1 year in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.50% and 97.53%, respectively, and there was difference between two groups (P < 0.05). After treatment, the systolic and diastolic blood pressure in two groups were significantly decreased (P < 0.05). The systolic and diastolic blood pressure in the treatment group was significantly lower than those in the control group (P < 0.05). After treatment, the low density lipoprotein, triglyceride and cholesterol levels in two groups were significantly decreased (P < 0.05). And the blood lipid level in the treatment group was significantly better than that in the control group (P < 0.05). After treatment for 1 year, complication rate in the control group was 32.50%, which was significantly higher than 13.58% in the treatment group, with significant difference between two groups (P < 0.05). During the treatment, the adverse reaction in the control and treatment groups were 21.25% and 7.41%, respectively, and there was difference between two groups (P < 0.05). Conclusion Naoxintong Capsules combined with benazepril can significantly improve blood pressure, blood lipid and complication in treatment of primary hypertension, which has a certain clinical application value.